指南与共识淋巴瘤造血干细胞移植与细胞治疗

将放疗与抗CD19嵌合抗原受体T细胞治疗整合用于复发/难治性非霍奇金淋巴瘤:多中心共识方法

Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
指南 / 共识 · Am J Hematol · 2023-11-11

抗CD19嵌合抗原受体T细胞治疗(CART)革新了复发/难治性B细胞非霍奇金淋巴瘤的结局,但仍受可及性、毒性和缓解持久性限制。本综述由Mayo Clinic专家提出将放疗与CART整合的多中心共识方法,涵盖桥接放疗、巩固放疗和挽救放疗的作用。

要点

  • 桥接放疗可在CART制备期间控制疾病、提高缓解率和局部控制、减瘤并降低细胞因子释放综合征严重程度。
  • 巩固放疗针对CART后残留病灶可改变复发模式,改善局部无复发生存和无进展生存。
  • 挽救放疗对CART后复发患者中局限复发者全面照射可获得有利生存结局,对弥漫复发者可姑息症状。

核心结论

  • 放疗是围CART期和挽救治疗中有前景的手段,可改善复发/难治性B细胞非霍奇金淋巴瘤患者的结局。
  • 围CART期疾病生物学了解甚少,需进一步研究放疗的最佳时机和剂量。

研究设计与样本

  • 本综述为多中心共识方法,由Mayo Clinic专家提出将放疗与CART整合的方法。

主要发现

  • 桥接放疗在CART前控制疾病、提高缓解率和局部控制、减瘤并降低细胞因子释放综合征严重程度,可能延长无病间期和生存,尤其在大块病灶患者中。
  • 巩固放疗针对CART后残留病灶改变复发模式,改善局部无复发生存和无进展生存。
  • 挽救放疗对CART后复发患者中局限复发者全面照射可获得有利生存结局,对弥漫复发者可姑息症状。

临床怎么用

  • 本研究中心(Mayo Clinic)的做法是将放疗与CART整合,具体方法见本综述提出的专家方法。

局限性

  • 围CART期疾病生物学了解甚少。
  • 需进一步研究放疗的最佳时机和剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor T-cell therapy (CART) has revolutionized the outcomes of relapsed and/or refractory B-cell non-Hodgkin lymphoma. However, CART is still limited by its availability, toxicity, and response durability. Not all patients make it to the CART infusion phase due to disease progression. Among those who receive CART, a significant number of patients experience life-threatening cytokine release syndrome toxicity, and less than half maintain a durable response with the majority relapsing in pre-existing sites of disease present pre-CART. Radiation therapy stands as a promising peri-CART and salvage treatment that can improve the outcomes of these patients. Evidence suggests that bridging radiotherapy prior to CART controls the disease during the manufacturing period, augments response rates and local control, cytoreduces/debulks the disease and decreases the severity of cytokine release syndrome, and may prolong disease-free intervals and survival especially in patients with bulky disease. Consolidative radiotherapy for residual post-CART disease alters the pattern of relapse and improves local recurrence-free and progression-free survivals. Salvage radiotherapy for relapsed post-CART disease has favorable survival outcomes when delivered comprehensively for patients with limited relapsed disease and palliates symptoms for patients with diffuse relapsed disease. The biology of the disease during the peri-CART period is poorly understood, and further studies investigating the optimal timing and dosing of radiation therapy (RT) are needed. In this review, we tackle the most significant challenges of CART, review and propose how RT can help mitigate these challenges, and provide The Mayo Clinic experts' approach on incorporating RT with CART.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Saifi O, Lester SC, Breen WG, et al. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach. Am J Hematol. 2023. PMID: 37950857. doi:10.1002/ajh.27155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。